Lincoln Pharmaceuticals Share Price Today

Lincoln Pharmaceuticals shareholders approve ₹1.80 dividend for FY26

Shareholders approved a final dividend of ₹1.80 per equity share for FY26. Two directors were reappointed despite significant dissent from institutional investors. Financial statements for FY26 were adopted with 99.99% votes in favor. Cost auditor remuneration for FY27 was ratified with near-unanimous support.

Lincoln Pharmaceuticals appoints Pradeep Yadav as SGM Quality Assurance

Pradeep Kumar Yadav appointed Senior General Manager, Quality Assurance. Appointment effective from September 24, 2026. Yadav brings over 20 years of pharmaceutical industry experience. Designated as Senior Management Personnel under SEBI LODR regulations.

Lincoln Pharmaceuticals accepts QA head resignation effective Sep 24

Lincoln Pharmaceuticals accepted Manoj Rai's resignation as Sr. General Manager-QA. Cessation is effective September 24, 2026, after close of business hours. Rai cited personal reasons and pursuit of new career opportunities. Disclosure made under Regulation 30 of SEBI LODR Regulations, 2015.

Lincoln Pharmaceuticals proposes ₹1.80 per share final dividend for FY26

Final dividend proposed at ₹1.80 per share (18%) for FY26. AGM scheduled for September 30, 2026, via video conference. Re-appointment of two whole-time directors up for vote. Cost auditor remuneration set at ₹2.5 lakh per annum plus expenses. Book closure runs from September 12 to September 30, 2026.

Lincoln Pharma sets September 11 record date for 32nd AGM

Record date for 32nd AGM set as September 11, 2026. Book closure runs from September 12 to September 30, 2026. Final dividend proposed at ₹1.80 per share for FY26. Meeting scheduled for September 30, 2026 via VC/OAVM.

Lincoln Pharma Q1FY27 net profit up 31% YoY to ₹36.23 crore

Lincoln Pharmaceuticals reported a consolidated net profit of ₹36.23 crore in Q1FY27, up 30.90% YoY, while total income rose 19.02% to ₹201.55 crore. EBITDA expanded 32.29% to ₹51.70 crore, outpacing revenue growth, and profit before tax rose 34.36% to ₹47.55 crore. The company plans to target annual revenue growth of 15-18% and reach ₹1,000 crore in revenue over three years, while expanding its export presence from over 60 countries to 90 countries. CRISIL Ratings reaffirmed its 'CRISIL A/Stable/CRISIL A1' ratings on the company's bank facilities.